[HTML][HTML] The deregulation of arachidonic acid metabolism in ovarian cancer
Q **a, W Gao, J Yang, Z **ng, Z Ji - Frontiers in Oncology, 2024 - ncbi.nlm.nih.gov
Arachidonic acid (AA) is a crucial polyunsaturated fatty acid in the human body, metabolized
through the pathways of COX, LOX, and cytochrome P450 oxidase to generate various …
through the pathways of COX, LOX, and cytochrome P450 oxidase to generate various …
Promising new drugs and therapeutic approaches for treatment of ovarian cancer—targeting the hallmarks of cancer
J Hillmann, N Maass, DO Bauerschlag, I Flörkemeier - BMC medicine, 2025 - Springer
Ovarian cancer remains the most lethal gynecological malignancy. Despite the approval of
promising targeted therapy such as bevacizumab and PARP inhibitors, 5-year survival has …
promising targeted therapy such as bevacizumab and PARP inhibitors, 5-year survival has …
[HTML][HTML] Effect of Cyclooxygenase-2 on prognosis in ovarian cancer patients
A Ibrahimov, R Sultan, T Bese - 2025 - actualgyn.com
Background: The aim of this study was to determine the association of clinicopathological
features with disease-free survival (DFS), overall survival (OS), and Cyclooxygenase-2 …
features with disease-free survival (DFS), overall survival (OS), and Cyclooxygenase-2 …
[PDF][PDF] Actual gynecology and obstetrics
A Ibrahimov, R Sultan, T Bese - actualgyn.com
Background: The aim of this study was to determine the association of clinicopathological
features with disease-free survival (DFS), overall survival (OS), and Cyclooxygenase-2 …
features with disease-free survival (DFS), overall survival (OS), and Cyclooxygenase-2 …